We have developed a noninvasive method to estimate splanchnic glucose uptake (SGU) in humans (oral glucose clamp technique [OG-CLAMP]), which combines a hyperinsulinemic clamp with an oral glucose load (oral glucose tolerance test). We validated this method in 12 nondiabetic subjects using hepatic vein catheterization (HVC) during an oral glucose tolerance test. During HVC, splanchnic blood flow increased from 1,395±64 to 1,935±109 ml/min, returning to basal after 180 min and accounted for 45±7% of SGU in lean and 19±5% in obese subjects (P < 0.05). SGU estimated during the OG-CLAMP was 22±2% of the glucose load, and this was significantly correlated (r = 0.90, P < 0.0001) with SGU (35±4%) and with first pass SGU (24±3%; r = 0.83, P < 0.001) measured during HVC. SGU was higher in obese than in lean subjects during OG-CLAMP (27±1% vs 18±3%, P < 0.01) and HVC (44±4% vs 26±5%, P < 0.05). In conclusion, SGU during the OG-CLAMP is well correlated to SGU measured during HVC. An increase in splanchnic blood flow is a major contributor to SGU in lean subjects. SGU is increased in obese subjects as measured by both methods. 
Introduction
The liver plays a central role in the maintenance of normal glucose tolerance. After glucose ingestion the liver switches from glucose production to glucose uptake (1) . Glucose uptake by the splanchnic area is regulated by the total amount of glucose presented to the splanchnic area and by its intrinsic ability to extract glucose (2) . It has been shown that substantial glucose uptake occurs after ingestion or intraduodenal infusion of glucose (SGU)' and the disposition of an oral glucose load in humans, two methods -hepatic vein catheterization (HVC) and the double tracer approach -have been used. Hepatic vein catheterization allows measurement of net hepatic glucose output (HGO) and hepatic glucose uptake can be calculated by subtracting hepatic glucose output from the amount of glucose given (4) . With this approach it has been concluded that up to 60% of an oral glucose load (OGL) is taken up by the liver (1) .
Studies using the double tracer method revealed a much lesser amount of glucose retained by the liver, ranging from 9% (5) to -30% (6) (7) (8) . Both methods have some limitations. Hepatic vein catheterization measures the net appearance of glucose on the systemic side of the liver, which is the amount of glucose transversing the liver after absorption from the gut, plus the remaining endogenous glucose production, which is suppressed by 50% after an oral glucose load (9) . Potential complications resulting from the invasive nature of this procedure, such as local hematomas at the puncture site, infections and thrombosis, and radiation exposure due to fluoroscopy prevent this method from being used in repetitive experiments. Results obtained by the double tracer method may be affected by incorporation of the glucose tracers into glycogen, which may lead to an inaccurate estimation of the rate of appearance (6) .
Limitations in the availability and in the repetitive use of both methods due to invasive procedures or radiation exposure have led us to evaluate a new, noninvasive approach to measure SGU by the combination of an euglycemic, hyperinsulinemic clamp and an oral glucose tolerance test (OGTT) during steady state of glucose disposal (oral glucose clamp [OG-CLAMP] method). This method could circumvent some of the problems with the methods mentioned above. To validate this method and to ensure that the different hormonal levels and secretion patterns do not influence measurement of SGU, we compared this method with the hepatic vein catheter technique in 12 nondiabetic subjects.
Methods
Subjects. 12 male, nondiabetic subjects participated in the study. Their ages ranged from 32 to 63 yr (mean 44.7±2.4 yr), their body mass index (BMI) from 24.0 to 38.5 kg/M2 (mean 30.9±1.5 kg/M2). These subjects were further subdivided into six lean (BMI 26.5±0.9 kg/M2) and six obese (BMI 35.3±1.2 kg/M2, P < 0.001, obese vs lean) sub-The study protocol was reviewed and approved by the Human Subjects Committee of the University of California, San Diego.
Experimental protocol. The order of the protocol was randomized. All studies were performed at 8:00 a.m. after a 10-12-h overnight fast. There was at least an interval of 1 wk between the OG-CLAMP and the hepatic vein catheterization study.
OG-CLAMP method
Glucose clamp study. The glucose clamp was performed as described previously under euglycemic conditions to quantitatively measure glucose uptake and maintain plasma glucose and serum insulin levels at the required levels (10, 11) . Using this approach, an antecubital vein was cannulated in an antegrade manner to administer infusates. A dorsal hand vein was cannulated in a retrograde fashion and kept in a warming device (720C) to facilitate venous sampling and provide arterialized venous blood. A loading dose of insulin was administered in a logarithmically decreasing manner over the next 10-min period and was followed immediately by a constant infusion rate (120 mU/M2 per min, for the next 420 min). The plasma glucose was maintained at the desired level throughout the study by monitoring the glucose level at 5-min intervals and adjusting the infusion rate of a 20% dextrose solution using a servo-control negative feedback principle. Thus, plasma glucose and insulin level were kept constant while the glucose infusion varied and the rate of glucose uptake assessed by the concomitant administration of 3-[3H]glucose served as a direct measurement of insulin effectiveness.
Splanchnic glucose uptake study. After 3 h of the insulin infusion, the rate of glucose disposal was at a steady state and significantly stimulated above basal values, and hepatic glucose production was suppressed. At this point a 75-g oral glucose load, which was not isotopically labeled, was administered to the subjects over 1 min and the plasma glucose was maintained at the previous steady state level by adjustment of the rate of glucose infusion to compensate for gastrointestinal glucose absorption. Completion of absorption was indicated when the steady state glucose infusion set was reached again. The rate of splanchnic glucose uptake was then calculated by subtracting the decrease in the amount of glucose infused from the known amount of glucose ingested. Blood was sampled from the dorsal hand vein before the clamp, at steady state and every 15 min after administration of the oral glucose load to determine insulin, glucagon and C-peptide levels.
Measurement ofHGO. Glucose 20-min intervals throughout the experiment, samples were obtained for determination of glucose concentration and specific activity. As the peripheral glucose infusion and the oral glucose load were not labeled and the glucose level was kept at the same level as before oral glucose administration, . a change in specific activity would indicate a change in glucose disposal rate.
HVC study. Under local anesthesia with 2% lidocaine, the femoral artery was punctured with an 18-gauge needle and a 5 French Teflon catheter was introduced. The catheter tip was positioned fluoroscopically at the level of the inferior margin of the sacroiliac joint so that it remained distal to the origin of the internal iliac artery. The femoral vein was similarly punctured, and a 6.5 French polyethylene catheter was advanced via the inferior vena cava into the right-sided hepatic vein under fluoroscopic control. The catheter was advanced into a wedge position and then withdrawn 1-2 cm. 1 ml of contrast medium was injected to visualize the tip of the catheter and to ensure that it was positioned in an area of adequate blood flow.
Splanchnic blood flow was estimated by a primed continuous infusion of indocyanine green (13) . The dye infusion was started via an antecubital vein 75 min before glucose ingestion and continued throughout the study. Blood was sampled simultaneously from the artery and the hepatic vein at 10-min intervals starting 45 min after the beginning of green dye infusion. At time zero, the subjects ingested 300 ml of a 75-g glucose solution over 5 min. Arterial and hepatic venous blood was sampled at 15-min intervals to determine the concentrations of glucose, C-peptide, insulin, glucagon, and indocyanine green for 4 h after glucose ingestion.
Splanchnic plasma flow was calculated by dividing the green dye infusion rate by arteriohepatic venous dye concentration difference. Splanchnic blood flow was estimated by dividing splanchnic plasma flow by (1 - 
Calculations OG-CLAMP method. GINF (mg/kg per min) was calculated for 20-min intervals and corrected for changes in pool fraction throughout the entire experiment. Activation of glucose disposal rate (GDR) and the time to steady state is faster the higher the insulin level, and in most subjects, GINF was constant between 120 and 180 min, and the mean value for GINF between 120 and 180 min was taken as the steady state for calculation. We have previously shown that in insulin-resistant obese subjects, activation is slower than in controls (14) , and, therefore, in some of the obese subjects GINF rose slightly between 120 and 180 minutes. In these subjects, the clamp was extended for an additional 40-60 min until steady state was reached, before administration of the oral glucose load. By this means, we confirmed that there was no further rise in GINF after 160 min, and used the GINF between 160 and 180 min for the steady state calculation. The validity of this approach was substantiated by the fact that the GINF returned to this same level after completion of absorption of the oral glucose load. Steady state conditions were further confirmed by the demonstration of stable plasma glucose specific activity in the cold-GINF experiment (see Fig. 3 ). After the oral glucose administration the respective GINF rates were subtracted from the steady state GINF. Multiplication of the difference in GINF with the respective time interval used for calculation (20 min) and the body weight, yields the absolute reduction of GINF in grams of glucose. The integrated reduction of GINF over the time required for glucose absorption was then subtracted from the known amount of glucose given (75 g). SGU was expressed as percentage of the administered glucose load retained by the splanchnic area.
HVC method. SGU during HVC was calculated by a modified formula reported by Ferrannini et al. ( 15 ) . The hepatic vein catheter technique allows measurement of the splanchnic blood flow (SBF), the glucose concentration in the artery (Ga) and in the hepatic vein (Ghv). In the fasting state, the splanchnic bed receives glucose via the hepatic and mesenteric arteries at the systemic glucose concentration; the glucose influx into the splanchnic area is therefore SBF-Ga. After administration of an OGL, the portal glucose level rises and the total glucose influx to the splanchnic area is then SBF Ga plus the rate of oral glucose resorption (OGR). The glucose efflux from the splanchnic bed is Ghv-SBF and must equal the sum of the total glucose influx after extraction. The relation is shown by the following equation:
SBF Ghv = (SBF -Ga + OGR) (I -F) (1) where F is the fractional extraction of glucose. Solving the equation for F, one obtains:
Lacking a method to measure portal glucose levels, the only unknown in this equation is OGR. However, assuming complete absorption of the glucose load, OGR can be substituted by the oral glucose load.
Completion of absorption of the glucose load can be assumed when the Noninvasive Method for Measurement of Splanchnic Glucose Uptake 2233 fasting hepatic glucose output is reached again, and the time required 3.0 for absorption of the glucose load T(abs) can then be used for calculating the integrated hepatic fractional extraction according to the following 2.5 formula: SGUfp(%) = OGLf 100
These equations do not account for residual hepatic glucose production, which has been shown to decrease to -40-50% of its fasting value (8) . Consequently, the weight of this term becomes very small relative to the glucose influx, and has been assumed to be zero. If a definitive value is assigned to it, the values for F and SGU will become slightly higher. This, however, applies to lean and obese subjects to the same extent and therefore does not change the correlation between the two methods or the comparison between the respective groups. Portal insulin levels were derived from arterial and hepatic vein Cpeptide levels assuming an equimolar release of C-peptide and insulin by the beta cell (17) , and neglecting the minimal C-peptide retention by the liver (18) (19) . C-peptide (20) and glucagon (21) were measured as described previously. Indocyanine green was analyzed by spectrophotometer after precipitation with sodium-desoxycholate (22) . Fig. 3 ) any absorbed glucose which bypasses the liver to enter the peripheral circulation will increase the plasma glucose level unless GINF is decreased by an exact amount so as to maintain constant delivery of glucose to the peripheral circulation. As shown in Fig. 2 A, within 10-20 min after oral glucose administration it was necessary to decrease GINF to maintain plasma glucose levels constant (Fig. 2 B) . GINF was gradually decreased to a nadir of 1.74±0.45 mg/kg per min at 60 min, reflecting posthepatic delivery of glucose from the gastrointestinal tract. After this time, GINF was gradually increased until the preloading rate of glucose infusion was reached 3-4 h after oral glucose administration. The rise in GINF reflects the decreasing influx of orally derived glucose, and the return of GINF to the preloading rate marks the end of the period of glucose absorption. The mean±SE time at which GINF returned to the original rate was 163±9 min. Plasma glucose levels were relatively stable throughout the 4-h postoral glucose loading period (Fig. 2 B) , indicating that the decrease in exogenous GINF was well matched to the posthepatic delivery rate of the orally ingested glucose. With this approach, the integrated decrease in the GINF over this 4-h period, subtracted from the amount of oral glucose given (75 g), is equal to the amount of oral glucose retained by the splanchnic bed, i.e., first pass splanchnic glucose uptake (see Methods). During the 4 h after administration of oral glucose, the circulating insulin levels remained constant (Fig. 2 B) . C-peptide levels rose over the first 30 min after oral glucose, but this effect on insulin secretion was small in comparison to the exogenous insulin infusion rates and did not appreciably alter the serum insulin concentrations (Fig. 2 B) . Serum glucagon levels decreased from a basal value of 125.7±14.0 ng/liter tõ 93.3+±9.4 ng/liter at steady state (P < 0.0001), and did not change following oral glucose administration.
As shown in Fig. 1 , Rd rises and HGO is suppressed by > 90%, as measured with the variable tracer infusion (hot-GINF) method. To determine whether the steady state disposal rate, achieved at the end of the glucose clamp period, is altered after oral glucose administration, OG-CLAMP studies were repeated in six subjects using a continuous infusion of 3-[3H]glucose at a rate of 0.6 1tCi/min. Since neither the peripheral glucose infusion, nor the oral glucose load were labeled in these studies, and since the circulating glucose level was kept constant before and during oral glucose administration, a change in glucose disposal rate after oral glucose would result in a corresponding change in glucose specific activity. As seen in Fig. 3 , after initiation of the insulin infusion, glucose specific activity decreased from 4,774±628 disintegrations per minute (dpm)/mg to 1,170±95 dpm/mg at the end of the glucose clamp phase, and following oral glucose administration, specific activity remained constant over the next 3 h. This shows that the glucose disposal rate was not altered by the oral glucose load, indicating that it is valid to extrapolate the steady state GDR to calculate SGU.
From these experiments we calculated that the cumulative hepatic glucose output during the 4 h after the oral glucose load was 58.2±1.5 g. This means that splanchnic glucose uptake of the 75-g glucose load was 22.4±2.0%.
Hepatic vein catheterization. Fig. 4 presents the mean glucose and insulin levels over the 4-h period after administration of the 75-g glucose load during the HVC study. As can be seen, arterial glucose values rose and then returned to baseline by 180 mmn. Arterial and hepatic vein insulin levels, as well as the calculated portal vein insulin levels (see Methods), are also shown in Fig. 4 . The area under the curve for insulin secretion over the 180 mmn was significantly higher in the portal vein (219 HtM/3 h) compared to the hepatic vein (122 MuM/3 h), yielding an hepatic insulin extraction ratio of 40.4±3.6%. After oral glucose administration, the splanchnic blood flow increased from 1,395±64 ml/min at basal to a peak of 1,935±109 ml/ mmn after 30 mm,. and then declined to 1,437±+122 ml/min at Noninvasive Method for Measurement of Splanchnic Glucose Uptake 2235 OG-CLAM Figure 6 . SGU in lean and obese subjects measured by the OG-CLAMP method and HVC. *P < 0.05; **P < 0.01. Comparison between OG-CL4MP and HVC. Both methods of assessing SGU yielded comparable absolute values when all subjects were considered as a group. To more thoroughly compare these methods, the relationship between individual values was examined. As shown in Fig. 5 , a highly significant correlation was observed between SGU, as measured during the OG-CLAMP, and SGU (r = 0.90, P < 0.0001), or first pass SGU (r = 0.83, P < 0.001) as measured by HVC. The correlation for SGU between the OG-CLAMP and the HVC method remained highly significant when a residual endogenous hepatic glucose production of 50% of basal was assumed during the HVC experiment (r = 0.86, P < 0.001).
Comparison between lean and obese subjects. The obese subjects were clearly insulin resistant, exhibiting a significantly lower GDR (5.78±0.4 mg/kg per min) than the control subjects (8.61±0.43 mg/kg per min, P < 0.001). The time required for resorption of glucose during the OG-CLAMP was not different between lean and obese subjects (157±39 min vs 170±21 min, P = 0.48). As indicated in Fig. 5 , the individual values for SGU were higher in the obese subjects compared to the controls by both HVC and OG-CLAMP methods, and these data are summarized in Fig. 6 . In the obese subjects posthepatic delivery of glucose was significantly lower compared to lean subjects during either the OG-CLAMP (54.5±1.1 vs 61.8±2.0 g, P < 0.01) or the HVC (42.1±3.0 vs 55.7±3.7 g, P < 0.05). SGU was significantly higher in obese compared to lean subjects during OG-CLAMP (27.2±1.4% vs 17.6±2.6%, P < 0.01) as well as during HVC (43.9±4.0% vs 25.8±4.9%, P < 0.05). This difference remained significant when a residual endogenous hepatic glucose production of 50% of basal was assumed during the HVC experiment (P < 0.05).
Discussion
The regulation of hepatic glucose uptake after glucose ingestion is determined by the hormonal milieu of insulin and glucagon, the glucose load to the liver, and the route of glucose delivery (3, 23) . In animal studies it has been shown that hepatic glucose uptake after oral glucose administration accounts for 30% of the glucose load (24, 25) . As the portal vein is not routinely accessible to cannulation in humans, it is not possible to measure the amount of glucose retained by the liver without including the component of extra hepatic splanchnic glucose consumption. The results obtained in humans, therefore, represent SGU. Currently, there are two experimental methods used to assess SGU in man: (a) HVC, and (b) the double-tracer method, in which oral and circulating glucose are traced with separate radioactive glucose isotopes. In the current studies, we have developed a third method, termed the OG-CLAMP to assess SGU in humans, and have applied this new method to quantitation of SGU in lean controls and insulin-resistant obese subjects.
The (27) . However, concurrent glycogenesis and glycogenolysis and/or glucose/glucose-6-phosphate cycling may lead to an over-or underestimation of SGU, depending on the isotopes used (6) . Like the HVC technique, this method also cannot accurately indicate completion of oral glucose absorption.
The OG-CLAMP method provides a relatively noninvasive measurement of SGU and is based on the combination of a euglycemic, hyperinsulinemic clamp and oral glucose administration. In this manner, a hyperinsulinemic euglycemic clamp is carried out for 3 h to establish a state of HGO suppression and steady state GDR; this is followed by ingestion of oral glucose and continuation of the glucose clamp for the subsequent 4 h. The following assumptions underly this method, and, therefore require validation: (a) HGO must be suppressed, and GDR must be at steady state before oral glucose administration. (b) The GDR must remain at steady state throughout the period of SGU measurement. (c) Since the plasma insulin level and/ or the insulin/glucagon ratio may influence SGU, an effect of the hyperinsulinemia and/or the high insulin/glucagon ratio during the OG-CLAMP on SGU must be negligible.
Each of the above assumptions has been verified by the results presented. Thus, using the variable tracer infusion (hot-GINF) method ( 12) , we demonstrated that GDR reached steady state and endogenous HGO was suppressed by 91% after 180 min of the hyperinsulinemic clamp. In a subset of subjects, an additional OG-CLAMP was performed using a continuous 3- [3H]glucose infusion, without labeling the glucose infusate. Since the plasma glucose level (and, therefore, the glucose pool) was kept constant throughout the study, any change in GDR would lead to a change in specific activity of the 3-
[3H]glucose tracer. As shown in Fig. 3 In this latter regard, we have used both the OG-CLAMP and HVC approach to assess SGU in lean control, compared to insulin-resistant obese subjects. We found that the time required for completion of gastrointestinal glucose absorption was essentially the same when measured with the two techniques, and, more importantly, was comparable between the two study groups. Interestingly, when SGU was compared, a 30-40% increase was observed in the obese subjects, and this was independently confirmed using both HVC and the OG-CLAMP approach. The mechanisms underlying this phenomenon are unclear at the present time. One might postulate that this is due to the increased splanchnic adipose tissue mass in the obese patients, leading to augmentation of the nonhepatic component of SGU. While our data do not directly disprove this notion, earlier studies have shown that nonhepatic SGU makes only a small contribution (-10%) to overall SGU (23) . Furthermore, total body adipose tissue mass accounts for only a minor portion of overall body glucose disposal. Therefore, even though obese subjects have a greater splanchnic adipose tissue mass, it seems unlikely that this makes a major contribution to glucose extraction, accounting for the increased SGU in the obese subjects. It seems more likely, therefore, that the increased SGU in obesity is due to enhanced hepatic glucose uptake. In this event, the mechanisms and physiologic significance of this observation deserve further study. It 
